LongevityHepatocyte epigenetic reprogramming medicine
On June 2, 2026 NewLimit said it plans a first human trial of its liver reprogramming medicine in 2027 (company blog).
Pipeline entry
Preclinical
Longevity
DeepTech + MedTechPreclinical
Bioprinting Human Tissue: What Works in the Lab, and What Would It Take to Reach Patients?
No bioprinted solid organ has been transplanted into a person, but bioprinting has produced striking lab and animal results. Here is what works today, what has reached early human testing, and what still stands in the way.
Explainer5 min read